Citius Pharmaceuticals, Inc.

Analysis for Ticker: CTXR

Citius Pharmaceuticals Inc develops specialty medicines for critically ill patients focusing on treatments for rare cancers and serious bloodstream infections. While it claims to be a medical company the internal math reveals a machine designed to transfer investor cash into the pockets of executives and outside laboratories through a series of debt traps. Since its inception in 2007 the company has never generated a profit instead accumulating a massive deficit of over 247$ million. This is a financial disaster because the company has already signed away the majority of its future potential earnings to larger pharmaceutical firms leaving regular shareholders to fund a business that primarily exists to pay its own managers and creditors.